Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01734382
- Locations
- 🇮🇱
Meir Medical center, Pediatrics, Kfar Sava, Israel
🇮🇹Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina, Roma, Lazio, Italy
🇺🇸Children's Hospital Los Angeles; Division of Rheumatoogy, Los Angeles, California, United States
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Pegylated Interferon Alfa (Peginterferon Alfa)
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 978
- Registration Number
- NCT01730508
- Locations
- 🇨🇳
The Second Gansu Province General Hospital, Lanzhou, China
🇨🇳Changzhou 3rd People's Hospital, Changzhou, China
🇨🇳The Eighth People's Hospital of Guangzhou, Guangzhou, China
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT01730456
A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT01729403
An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT01727986
An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 274
- Registration Number
- NCT01725386
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
- Conditions
- Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 743
- Registration Number
- NCT01724021
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT01724294
ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 144
- Registration Number
- NCT01723878
- Locations
- 🇪🇸
Hospital General de Granollers; Servicio de Oncologia, Granollers, Barcelona, Spain
🇪🇸Hospital General de Teruel Obispo Polanco; Servicio Oncologia, Teruel, Spain
🇪🇸Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain
An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy
- Conditions
- Anemia
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT01716559